Anika Therapeutics Inc. has appointed Stephen (Steve) Griffin as President and Chief Executive Officer, effective February 1, 2026. Cheryl Blanchard, the current CEO, will become Executive Chair of the Board of Directors. John (Jack) B. Henneman, III has been named Lead Independent Director, and Susan N. Vogt will resign from the Board, also effective February 1, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anika Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622018-en) on January 08, 2026, and is solely responsible for the information contained therein.